Novo Nordisk A/S (NVO)

Novo Nordisk A/S records an AlphaScore of 68/100 within the Healthcare sector. The company displays an impressive return on equity of 59.81% and a high gross margin of 80.98%. A notable strength is the value subscore of 93, suggesting attractive valuation parameters. A primary risk is the modest growth subscore of 30, reflecting restricted expansion across the reported metrics.

Written 11/10/2026, 00:23:19 UTC · Snapshot 11/10/2026